Trastuzumab Deruxtecan
Daiichi Sankyo,AstraZeneca
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'destiny,crc,02', 'daiichi', 'astrazeneca']
 &amp; during the oral abstract session at the 2023 annual meeting, presented the key updates from the phase ii destiny-crc02 study (nct04744831). learn more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry